Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

101Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In a previous trial among 137 previously untreated patients with multiple myeloma, the combination of thalidomide-dexamethasone induced remission in 66% of patients, including complete remission in 13%. In an attempt to induce more frequent remissions, we added bortezomib to this program. Between 7/03 and 3/06, 38 newly diagnosed patients with multiple myeloma received at least one, but no more than 3, courses of bortezomib in a dose of 1.3 mg/m 2 IV ×4; dexamethasone 20 mg/m 2 PO for 4 days beginning on days 1, 9, 17; thalidomide 100 mg PO daily increasing to a maximum of 200 mg. There was rapid onset of remission in 33 patients (87%) including 6 patients with complete remission (16%). Most side effects were preventable, but otherwise were usually mild and reversible. After a median of 4 months, 25 eligible patients received intensive therapy with high-dose melphalan supported by autologous blood stem cells, so that the myeloma was in complete remission in 14 patients (37% of all patients). The combination of bortezomib-thalidomide-dexamethasone was a highly effective primary treatment for newly diagnosed patients with multiple myeloma.

Cite

CITATION STYLE

APA

Wang, M., Giralt, S., Delasalle, K., Handy, B., & Alexanian, R. (2007). Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 12(3), 235–239. https://doi.org/10.1080/10245330701214236

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free